Tia S. Thomas

Tia S. Thomas

Auto-generated profile, based on publicly available information

Tia S. Thomas

Institute for Stroke and Cerebrovascular Diseases McGovern Medical School at UTHealth Houston Houston Texas USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2025 in Movement Disorders
Verified
Journal Article
Open access
MSMya Caryn Schiess
Mya Caryn Schiess
JSJessika Suescun
Jessika Suescun
JMJuan D. Martinez‐Lemus
Juan D. Martinez‐Lemus
CGCharles Green
Charles Green
TTTia S. Thomas
Tia S. Thomas
TETimothy Ellmore
Timothy Ellmore
Background: Neuroinflammation contributes to Parkinson's disease (PD) progression and motor dysfunction. Allogeneic human mesenchymal stem cells (allo‐hMSCs) may reduce neuroinflammation and improve motor symptoms. Objectives: To evaluate the efficacy of repeated intravenous doses of 10 × 10 6 /kg allo‐hMSCs in improving motor symptoms in patients with PD (PwP). Methods: In this phase 2, randomized, placebo‐controlled trial (November 2020–July 2023), mild‐to‐moderate PwP received either three allo‐hMSC infusions, one placebo followed by two allo‐hMSC infusions, or three placebo infusions at 18‐week intervals. Follow‐up lasted 88 weeks. The primary outcome was a >70% posterior probability (PP) of a difference in the proportion of participants with ≥5‐point improvement in OFF‐medication Movement Disorder Society Sponsored Revision of the Unified Parkinson's Disease Rating Scale‐Part III (MDS‐UPDRS‐III) at week 62. Bayesian analysis was conducted using R v4.2.0. Results: Forty‐five PwP were enrolled. A larger proportion of subjects achieved a ≥5‐point improvement in MDS‐UPDRS‐III in the three‐infusion arm compared with placebo at week 62 (mean difference [MD]: 5.0%, PP = 93.7%), translating to a 16.9‐point improvement in MDS‐UPDRS‐III in the three‐infusion arm compared with a 14.6‐point improvement in the placebo arm. Conversely, fewer subjects in the two‐infusion arm compared with placebo showed ≥5‐point improvement at week 62 (MD: –62.4%, PP ≥ 99.9%), translating to only a 3.9‐point improvement in MDS‐UPDRS‐III in the two‐infusion arm. However, improvement in MDS‐UPDRS‐III was seen across all treatment arms. Adverse events were mild and transient. Conclusions: Three infusions of 10 × 10 6 allo‐hMSCs/kg improved motor function in mild‐to‐moderate PwP, while two infusions showed less improvement than placebo. To address this discrepancy, future studies should conduct functional potency assays to understand batch‐to‐batch variability affecting clinical efficacy. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

1 July 2025 in Journal of Pain Research
Verified
Journal Article
Open access
PDF file
DDDeniz Dishman
Deniz Dishman
CGCatherine Gonzalez
Catherine Gonzalez
TTTia Thomas
Tia Thomas
HIHari Kishan Indupuru
Hari Kishan Indupuru
SKSeokhun Kim
Seokhun Kim
SSSean Savitz
Sean Savitz
Background: Pain is one of the most common sequelae after a stroke. Yet it is under-recognized, under-treated, and under-investigated, with no standard care guidelines for management during post-stroke recovery. Purpose: The primary objective of this study was to capture the prevalence of pain and different pain types in stroke survivors. Patients and Methods: The study included stroke survivors who completed a pre-visit telehealth review of systems instrument between March 1, 2020, and February 28, 2022. 442 out-patient subjects were identified and matched to their respective electronic health record from the incident stroke. Subjects were divided into pain and no-pain groups based on self-report of post-stroke pain. Bivariate analyses were performed to test the association between the patient’s demographic and clinical characteristics and pain using t-tests or Wilcoxon rank sum tests for continuous variables and chi-square tests for categorical variables. Random forest imputation was used to address missing values. Multivariable analysis was performed using the logistic regression method. Results: Of the 442 subjects, 58% (N=258) reported pain, with 56% experiencing multiple pain types. Musculoskeletal pain (36%), Neuropathic pain (22%), and Headaches (17%) were the most common pain types. Only 20% of patients reporting pain used analgesics, with gabapentin (43%) and opioids (11%) being the most common prescriptions. Obstructive sleep apnea (OSA), history of recreational drug use, and gender showed a significant relationship with pain in univariate analysis. In the final logistic regression model, OSA (OR: 3.37, 95% CI: 1.34– 9.80, p: 0.015) and history of recreational drug use (OR: 2.05, 95% CI: 1.16– 3.83, p: 0.018) remained significant. The model achieved moderate discrimination with an AUC of 0.62. Conclusion: Over half of stroke survivors experienced pain, with 30% reporting multiple pain types. The low rate of analgesic use (20%) and significant proportion of patients experiencing pain highlight the critical need for evidence-based pain management guidelines in post-stroke care.